

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

B&K CORPORATION LIMITED
青城新藥生物科技（青島）股份有限公司

(formerly known as 華芒生物科技（青島）股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2396)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the annual report of the Company for the year ended 31 December 2025 (the “**2025 Annual Report**”) and the interim report of the Company for the six months ended 30 June 2026 (the “**2026 Interim Report**”). Unless otherwise defined, terms used herein shall have the same meaning as those defined in the 2025 Annual Report and the 2026 Interim Report.

The Company wishes to provide supplemental information regarding the likely timeframe of the Core Product, Pro-101-2 for DFUs, as follows:

As at 31 December 2025

The Phase II clinical trial planned to enroll 160 patients. The Company was accelerating patient enrollment in the Phase II clinical trial of DFUs and aimed to complete the enrollment of all patients in the first half of 2026. With reference to the then development status, the Company planned to (i) complete the Phase II clinical trial in the second quarter of 2027 and initiate Phase III in the third quarter of 2027 and complete the trial in the second quarter of 2029 in China; (ii) submit an IND application to the FDA to initiate a Phase III clinical trial in the first quarter of 2027 in the U.S., and (iii) submit a CTN application to the PMDA to commence a Phase III clinical trial in the first quarter of 2027 in Japan and initiate the Phase III clinical trials in both countries in the third quarter of 2027.

Taking into account the then development status as at 31 December 2025, and subject to the uncertainties as further explained below, the Company planned to reach commercialization and launch Pro-101-2 in China in 2030.

As at 30 June 2026

Pro-101-2 has completed full patient enrollment, with 160 trial participants enrolled, in July 2026. With the enrollment for the clinical trial in China completed, the Company was actively advancing clinical data consolidation and preparing supplementary materials for submission of clinical trial applications in the United States and Japan. With reference to the latest development status, the Company planned to (i) complete the Phase II clinical trial in the first quarter of 2027 and initiate Phase III in the second quarter of 2027 and complete the trial in the second quarter of 2029 in China; (ii) submit an IND application to the FDA to initiate a Phase III clinical trial in the first quarter of 2027 in the U.S., and (iii) submit a CTN application to the PMDA to commence a Phase III clinical trial in the first quarter of 2027 in Japan and initiate the Phase III clinical trials in both countries in the third quarter of 2027.

Taking into account the latest development status as at 30 June 2026, and subject to the uncertainties as further explained below, the Company planned to reach commercialization and launch Pro-101-2 in China in 2030.

The aforesaid estimated timeline of the commercialization remains highly uncertain given various factors that are beyond the control of the Group, including but not limited to the results of the clinical trials, discussion with the regulatory authorities on the design and protocol of subsequent trials, the possibility of conducting additional trials as may be requested by the regulatory authorities, and the approval and directions to be made by the regulatory authorities.

In addition, the successful commercialization of the Core Products depends on a number of factors, including: (i) positive safety and efficacy results from our clinical trials; (ii) the successful recruitment and retention of patients, as well as the completion of clinical trials; (iii) adequate supply of drug products used either in combination with or as comparators to the Core Products during clinical trials; (iv) the performance of any third parties we engage to conduct clinical trials, and their adherence to our protocols and relevant laws without undermining the integrity of the resulting data; (v) the abilities and expertise of our collaborators; (vi) the receipt of regulatory approvals; (vii) commercial manufacturing capacity; (viii) the successful commercial launch of the Core Products, if and when approved; (ix) competition from other drug candidates and drugs; (x) obtaining, maintaining, and enforcing patents, trademarks, trade secrets, and other intellectual property protections, as well as regulatory exclusivity, for the Core Products; (xi) successfully defending against any claims brought by third parties alleging that we have infringed, misappropriated, or otherwise violated their intellectual property; and (xii) the continuation of an acceptable safety profile for the Core Products following regulatory approval.

THE COMPANY CANNOT GUARANTEE THAT THE COMPANY WILL BE ABLE TO ULTIMATELY SUCCESSFULLY DEVELOP AND MARKET PRO-101-2.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Save as disclosed above, all the other information and contents in the 2025 Annual Report and the 2026 Interim Report remain unchanged. The information contained in this announcement does not affect the other information contained in the 2025 Annual Report and the 2026 Interim Report and should be read in conjunction with the 2025 Annual Report and the 2026 Interim Report.

By order of the Board
B&K Corporation Limited
Ms. JIA Lijia
Chairperson and Executive Director

Qingdao, the PRC
2 October 2026

As of the date of this announcement, the Board comprises (i) Ms. JIA Lijia, Mr. WANG Kelong, Dr. ZHAI Junhui and Mr. MIAO Tianxiang as executive Directors; (ii) Ms. LIN Ying and Mr. YUAN Fei as non-executive Directors; and (iii) Mr. FOK Chi Tat Michael, Mr. LI Jiayan and Mr. YUE Yichun as independent non-executive Directors.